Kachi– Production
25,000tpa LCE; Capex ~US$400 -550m .
Potential to expand to 100,000tpa LCE.
Phased expansion from 10,000tpa LCE - Capex ~US$100-140m
Ebitda annual - US$155m , assume conservative
US$11,000/t lithium carbonate CIF future price
Targeting lower up front start up costs with Solar for energy and Capital cost reductions.
Payback conservative 3 to 4 years.
- Forums
- ASX - By Stock
- LKE
- Ann: PFS Presentation
Ann: PFS Presentation, page-19
Featured News
Add LKE (ASX) to my watchlist
|
|||||
Last
3.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $56.72M |
Open | High | Low | Value | Volume |
3.5¢ | 3.5¢ | 3.4¢ | $58.86K | 1.714M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 1317660 | 3.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.5¢ | 259343 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 1317660 | 0.034 |
18 | 1056596 | 0.033 |
8 | 378281 | 0.032 |
17 | 1885486 | 0.031 |
23 | 1435432 | 0.030 |
Price($) | Vol. | No. |
---|---|---|
0.035 | 259343 | 3 |
0.036 | 765629 | 6 |
0.037 | 1112055 | 7 |
0.038 | 1332413 | 10 |
0.039 | 1393027 | 6 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
NEWS
Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
LKE (ASX) Chart |